Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remibrutinib (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CLOU064C12302; REMODEL-2
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 17 Jan 2023 Planned End Date changed from 23 Nov 2029 to 30 Oct 2030.
    • 17 Jan 2023 Planned primary completion date changed from 31 Oct 2025 to 30 Apr 2026.
    • 28 Jun 2022 Results from two studies (REMODEL I/II) assessing efficacy, safety, and tolerability of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis presented at the 8th Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top